Boston, MA – The Chinese Antibody Society (CAS) and Cambridge Healthtech Institute (CHI) today announced a strategic partnership that strengthens the continuous efforts of CAS to promote the globalization of antibodies developed in China, while enhancing CHI’s influence on Chinese biopharmaceutical professionals working in the therapeutic antibody sector. The two organizations are teaming up to integrate their services and provide member benefits such as discounted registration rates for selected CHI events and conferences. Leveraging the respective strengths of both organizations, the new partnership is expected to spark interest among professionals seeking to expand their networks and engage in the global community of R&D, manufacturing, and commercialization of antibody-based therapeutics.

“Chinese Antibody Society is the first and so far, the only global organization for Chinese professionals focusing on therapeutic antibodies. CHI is the leader in conference and event development organizing many international conferences in life sciences including PEGS and PepTalk. Therefore, this newly partnership with CHI will allow CAS’ members to attend CHI’s events and conferences with discounted registration rates in the future.” Commented, Dr. Shawn Shouye Wang, President of CAS, “Partnering with CAS will increase the visibility of CHI and its conferences to CAS’ members, and is therefore for mutual benefits”.

Jim MacNeil, Vice President of Marketing at CHI acknowledged, “China is a biopharmaceutical powerhouse, and we (CHI) are committed to supporting global research, sharing innovative discovery programs, and advancements in technology. We look forward to collaborating with CAS to bring together key industry leaders and visionaries advancing the field.”

About Chinese Antibody Society (CAS)

Founded in April 2016, the Chinese Antibody Society (CAS) is a nonprofit, non-governmental, international, and professional organization registered in the Commonwealth of Massachusetts of the United States. The mission of CAS is to bring together industry, academics, healthcare providers, and investors to connect, communicate, and collaborate on the discovery, development, manufacturing, and marketing of therapeutic antibodies. Through its programs and services, the CAS serves as a nurturing platform to foster the productive interaction and networking among its members, particularly those in both China and the United States. It also functions as a bridge to accelerate the FDA approval and marketing of antibody-based therapeutics developed in China.

About Cambridge Healthtech Institute (CHI)

Founded in 1992, Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Cambridge Marketing Consultants, Barnett Educational Services, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.